IRVINE, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint® Neuro Navigation System will be exhibited at the American Epilepsy Society (AES) Annual Meeting taking place on December 2 - 6, 2016, in Houston, Texas. The opening symposium entitled “Epilepsy Specialist Symposium: Choosing from the Feast of Epilepsy Surgery Procedures: How Do We Decide the Best Course for Each Patient?” will address ways in which different surgical approaches might be selected or sequenced in order to provide optimal benefit for individual patients.
“Among the epilepsy treatment approaches to be discussed in the opening symposium is our ClearPoint Neuro Navigation System," stated Frank Grillo, Chief Executive Officer for MRI Interventions. “The ClearPoint System allows surgeons to plan, target, and adjust trajectories under real-time MRI-guided visualization for highly accurate placement of laser fibers and stimulation electrodes, which is a reason we continue to see strong adoption of the ClearPoint System in those hospitals that offer state-of-the-art epilepsy therapies for their patients. By performing these minimally-invasive neurosurgical procedures entirely in the MRI suite, risks associated with the intra-operative transport of patients between the operating room and the MRI suite, otherwise necessary to complete some procedures, are eliminated. In addition, patients do not have to endure the placement of a large stereotactic headframe, resulting in an improved patient experience.”
AES attendees are invited to visit the MRI Interventions booth (#216) to learn about the ClearPoint Neuro Navigation System. ClearPoint goes beyond planning, enabling surgeons to perform a wide range of minimally-invasive neurosurgical procedures under real-time MRI visualization.
About MRI Interventions, Inc.
Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally-invasive surgical procedures in the brain. The ClearPoint System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally-invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company’s ability to obtain additional financing; estimates regarding the sufficiency of the Company’s cash resources; future revenues from sales of the Company’s ClearPoint System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, both of which have been filed with the Securities and Exchange Commission. Contact: Wendelin Maners, VP, Marketing MRI Interventions, Inc. 949-900-6833